Latest Glycoproteins Stories
ROCHESTER, N.Y., Dec.
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
SUZHOU, China, Dec. 8, 2014 /PRNewswire/ -- Adagene Inc.
ROCHESTER, N.Y., Dec. 3, 2014 /PRNewswire/ -- Vaccinex Inc. announced today that Dr.
MAB242P, the most recently developed antibody, is the first MBS antibody to recognize both GI and GII strains of norovirus.
PhosImmune and PureMHC Working Together On Immunotherapies for Cancer CHARLOTTESVILLE, Va. and AUSTIN, Texas, Oct. 22, 2014 /PRNewswire/ -- PhosImmune Inc.
Management Responds To Inquiries Concerning Discovery Capabilities For Anti-Ebola Treatments SAN DIEGO, Oct. 21, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc.
PLYMOUTH, Minn., Oct.
-- CIAO!(TM) Technology Maximizes Selectivity of Conditionally Active Antibodies -- SAN DIEGO, Oct.
- An imitative word; an onomatopoetic word.